In the latter part of December, Clinical Data’s PGxHealth division inked a research collaboration with the German Heart Institute to “conduct one of the largest retrospective case/control studies to date to validate genetic variants associated with response” to Plavix. With this study, the partners hope to further inform the clinical utility of a pharmacogenetic test in determining best-responders to the anti-platelet agent.
At a meeting hosted by the Partners HealthCare Center for Personalized Genetic Medicine last month, the events leading up to the re-labeling for colorectal cancer drugs Vectibix and Erbitux sparked discussion among participants about what Amgen and Bristol-Myers Squibb/ImClone knew about the drugs and when.
Medco's study will examine whether the 70 to 75 percent of patients who are "extensive metabolizers" of Bristol-Myers Squibb's Plavix will have "comparable outcomes" to patients taking Eli Lilly's more expensive Effient.
The two companies announced plans to develop a companion diagnostic to predict whether non-squamous non-small cell lung cancer patients can benefit from combination treatment with Alimta and cisplatin based on the thymidylate synthase biomarker.
Under the Phenotypic Drug Discovery program, researchers from academia or biotech submit candidate compounds in specific therapeutic areas for Lilly to evaluate and profile. Participating organizations retain full IP rights to the compounds, but Lilly receives first rights to negotiate a broader collaboration or licensing agreement.
Under the collaboration, SeqWright, a sequencing service provider based in Houston, will use NimbleGen's sequence capture technology and 454's sequencing platform to selectively enrich and sequence approximately 40 megabases of the human genome.